• Kripto Paralar
  • Tahmin Piyasaları
  • Haberler
  • Ajansal İşlem
  • Yazılar
  • Ligler

Kripto Paraları Ara

Trend Kripto Paralar

CoinRithm

Şirket

Tüzel Kişilik
Bees-x Limited
Şirket Numarası
13308136
Kuruluş Yeri
England and Wales
Kayıtlı Ofis
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm, Bees-x Limited tarafından işletilen bir bilgi ve araştırma hizmetidir. Düzenlenmiş faaliyetleri yürütmek üzere Financial Conduct Authority (FCA) tarafından yetkilendirilmemiştir ve bu sitedeki hiçbir içerik finansal tavsiye değildir.

Keşfet

Kripto ParalarTahmin PiyasalarıHaberlerYazılarAgent ArenaLigler

Özellikler

Kontrol PaneliTicaret SimülasyonuAjansal İşlemPortföyİzleme ListesiAyarlar

Şirket

HakkımızdaMetodolojiKullanım ŞartlarıGizlilik PolitikasıÇerez PolitikasıFeragatname

Destek

Destekle İletişimSSSGeliştirici kitiMCP belgeleri

Sosyal Medya

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Tüm hakları saklıdır.
Google Play'de edininApp Store'dan İndirin
  • Ana Sayfa
  • PiyasalarTahmin Piyasaları
  • Haberler
  • Kontrol Paneli
  1. Tahmin Piyasaları
  2. Health & Medicine
  3. When will the FDA reclassify BPC-157 to Category 1?
When will the FDA reclassify BPC-157 to Category 1?

When will the FDA reclassify BPC-157 to Category 1?

4.0% (24s)Health & MedicineOne-Off19g
KalshiKalshiKullanılabilirliği kontrol etKYC gerekli%2 ücret
Güncel ima edilen olasılık
Before July
Before July 5%+4.0%
6 seçenek arasında lider
Piyasa kalitesi

28 / 100

Düşük kalite
24s Hacim

₺7,6

Likidite

₺5,5 B

Düşük likidite
Alis / Satis

1.0% / 6.0%

Spread

500.0%

Geniş spread
Piyasa verileri

8 dakika önce guncellendi

24 Mar 26 14:001 Tem 26 3:59

Trendler

Sonuç24sOlasılık

Seçilen sonuç

Before July5%

Kurallar

If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Apr 15, 2026, then the market resolves to Yes.

Kalshi
  • The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
  • Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before May 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jul 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.

İlgili Piyasalar

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

₺7,9 Mn
Evet: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

₺886,9 B
Evet: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

₺466,8 B
Evet: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

₺67,1 B
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

₺24,7 B
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

₺7,3 B
2025: 0%Manifold MarketsMANIFOLD MARKETS

Bu konularda aktif

BitcoinBTC$62,760.97+1.77%EthereumETH$1,655.44+1.05%SolanaSOL$65.09+0.86%DogecoinDOGE$0.0849+1.04%XRPXRP$1.12-0.11%BNBBNB$597.01+1.46%

İlgili Haberler

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Kurallar

If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Apr 15, 2026, then the market resolves to Yes.

Kalshi
  • The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
  • Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before May 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jul 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.